Processing

Please wait...

Settings

Settings

Goto Application

1. WO2009008696 - PHARMACEUTICAL COMPOSITION COMPRISING THE COMBINATION OF A TRIAZOLOBENZODIAZEPINE AND A SELECTIVE SEROTONIN REUPTAKE INHIBITOR

Publication Number WO/2009/008696
Publication Date 15.01.2009
International Application No. PCT/MX2008/000085
International Filing Date 04.07.2008
Chapter 2 Demand Filed 30.04.2009
IPC
A61K 31/5517 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
551having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
55131,4-Benzodiazepines, e.g. diazepam
5517condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
A61K 31/4525 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
4525containing a five-membered ring with oxygen as a ring hetero atom
A61P 25/24 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
24Antidepressants
CPC
A61K 31/4525
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
445Non condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
4525containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/5517
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
551having two nitrogen atoms, e.g. dilazep
55131,4-Benzodiazepines, e.g. diazepam ; or clozapine
5517condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Applicants
  • WORLD-TRADE IMPORT-EXPORT, WTIE, AG. [CH]/[CH] (AllExceptUS)
  • GARCÍA ARMENTA, María Elena [MX]/[MX] (UsOnly)
  • SANTOS MURILLO, Josefina [MX]/[MX] (UsOnly)
  • ÁLVAREZ OCHOA, Víctor Guillermo [MX]/[MX] (UsOnly)
Inventors
  • GARCÍA ARMENTA, María Elena
  • SANTOS MURILLO, Josefina
  • ÁLVAREZ OCHOA, Víctor Guillermo
Agents
  • PARDAVELL JUÁREZ, María Angélica
Priority Data
MX/a/2007/00832106.07.2007MX
Publication Language Spanish (ES)
Filing Language Spanish (ES)
Designated States
Title
(EN) PHARMACEUTICAL COMPOSITION COMPRISING THE COMBINATION OF A TRIAZOLOBENZODIAZEPINE AND A SELECTIVE SEROTONIN REUPTAKE INHIBITOR
(ES) COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE LA COMBINACIÓN DE UNA TRIAZOLOBENZODIAZEPINA Y UN AGENTE INHIBIDOR SELECTIVO DE LA RECAPTURA DE SEROTONINA.
(FR) COMPOSITION PHARMACEUTIQUE COMBINANT UNE TRIAZOLOBENZODIAZÉPINE ET UN AGENT INHIBITEUR SÉLECTIF DE LA RECAPTURE DE LA SÉROTONINE
Abstract
(EN)
The present invention concerns a pharmaceutical composition formed by the synergistic combination of a selective serotonin reuptake inhibitor, such as the active principle: Paroxetine hydrochloride hemihydrate and an agent belonging to the triazolobenzodiazepine group, such as the active principle: Alprazolam, as well as pharmaceutically acceptable excipients; which are formulated in a single dosing unit to be administered by oral means, said unit being prescribed for the treatment and control of major depressive episodes, symptoms of Obsessive-Compulsive disorder (OCD), panic attacks with or without agoraphobia, generalized anxiety disorders, social phobia and post-traumatic stress disorder.
(ES)
La presente invención está relacionada con una composición farmacéutica compuesta por la combinación sinérgica de un agente inhibidor selectivo de la recaptación de serotonina, como lo es el principio activo: Paroxetina hemidrato del Clorhidrato de Paroxetina y de un agente perteneciente al grupo de las triazolobenzodiazepinas, tal como lo es el principio activo: Alprazolam, además de excipientes farmacéuticamente aceptables; los cuales se encuentran formulados en una sola unidad de dosificación para ser administrada por vía oral, misma que está indicada para el tratamiento y control de episodios depresivos mayores, síntomas del trastorno Obsesivo - Compulsivo (TOC), trastornos de pánico con o sin agorafobia, trastornos de ansiedad generalizada, fobia social y desorden de estrés postraumático.
(FR)
La présente invention concerne une composition pharmaceutique combinant de manière synergique un agent inhibiteur sélectif du recaptage de la sérotonine, tel que le principe actif paroxétine hémidrate du chlorhydrate de paroxétine, et un agent appartenant au groupe des triazolobenzodiazépines, tel que le principe actif alprazolam, et contenant également des excipients pharmaceutiquement acceptables, lesquels sont formulés en une seule unité de dosage administrée par voie orale et indiquée dans le traitement et le contrôle d'épisodes dépressifs majeurs, des symptômes des troubles obsessionnels compulsifs (TOC), des troubles de panique avec ou sans agoraphobie, des troubles d'anxiété généralisée, de la phobie sociale et des troubles liés à un stress post-traumatique.
Latest bibliographic data on file with the International Bureau